ArticleThe EPMA journal2020
Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine.
Article in The EPMA journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 19 citations in OpenAlex.
- Integrated Proteomic and Metabolomic Analyses of Cerebrospinal Fluid from Pediatric Patients with Diffuse Intrinsic Pontine Glioma.International journal of molecular sciences · 2026Article
- Cerebrospinal Fluid in Pediatric Neuro-Oncology: Molecular Diagnosis, Disease Monitoring, and Clinical Translation.International journal of molecular sciences · 2026Review
- Article
- Is leptomeningeal dissemination in oligodendroglioma predictable? Evidence from a scoping review.Frontiers in oncology · 2026Review
- Causal Relationship Between Butyrate and Dyspepsia: Evidence From Two-Sample Mendelian Randomization Analysis of CSF Metabolites.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Lipid Biomarkers in Glioma: Unveiling Molecular Heterogeneity Through Tissue and Plasma Profiling.International journal of molecular sciences · 2025Article
- A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.Neuro-oncology · 2025Review
- Causal effect between circulating metabolic markers and glioma: a bidirectional, two-sample, Bayesian weighted Mendelian randomization.Discover oncology · 2025Article
- Exploratory profiling of metabolites in cerebrospinal fluid using a commercially available targeted LC-MS based metabolomics kit to discriminate leptomeningeal metastasis.Cancer & metabolism · 2025Article
- Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility.BioMedicine · 2025Review
- The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis.BMC cancer · 2024Article
- Review
- The genomic alterations in glioblastoma influence the levels of CSF metabolites.Acta neuropathologica communications · 2024Article
- Monitoring central nervous system tumour metabolism using cerebrospinal fluid.Frontiers in oncology · 2024Review
- Characterization and clinical implications of different malignant transformation patterns in diffuse low-grade gliomas.Cancer science · 2023Article
- Global metabolomics study on the pathogenesis of pediatric medulloblastoma via UPLC- Q/E-MS/MS.PloS one · 2023Article
- Lipid Alterations in Glioma: A Systematic Review.Metabolites · 2022Review
- Review
- Glioma glycolipid metabolism: MSI2-SNORD12B-FIP1L1-ZBTB4 feedback loop as a potential treatment target.Clinical and translational medicine · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma shows progression presenting as malignant transformation or leptomeningeal metastasis (LM). However, longitudinal biopsy of brain parenchyma is difficult due to its critical location, whereas cerebrospinal fluid (CSF) can be obtained serially with a little invasiveness of puncture. Thus, if we could find a biomarker for glioma progression, we could predict such event and determine therapeutic interventions as early as possible. In this study, we examined whether cerebrospinal fluid (CSF) metabolome profiles can reflect glioma grade, difference with non-glial tumor, and LM status. We selected 32 CSF samples from glioma patients, and compared them with 10 non-tumor control and seven non-glial brain tumor (medulloblastoma) samples. A total of 10,408 low-mass ions (LMIs) were detected as a candidate of metabolites using mass spectrometry, and representative LMIs were identified via the Human Metabolome Database. Grade IV gliomas showed eight LMIs, including acetic acid, of higher levels (summed sensitivity and specificity > 180%) than grade III gliomas. Grade IV gliomas demonstrated more abundant 30 LMIs, including glycerophosphate, compared with medulloblastoma, but none was mutually exclusive. Phospholipid derivatives were significantly more abundant in LM (-) than LM (+) gliomas regardless of glioma grade. LMIs representative of LM (+) gliomas were derivatives of glycolysis. We also verified discriminative LMIs based on mean expression level of each LMI (Student
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.